16.15  -0.005 (-0.03%)		01-20 16:00
Open: 15.91 High: 16.245 Volume: 4,569,328		Pre. Close: 16.155 Low: 15.91 Market Cap: 51,021(M)

Short term
Mid term
Targets	6-month :	19.24	1-year :	22.48
Resists	First :	16.47	Second :	19.24
Pivot price	16
Supports	First :	15.07	Second :	14.19
MAs	MA(5) :	16.22	MA(20) :	15.83
	MA(100) :	14.69	MA(250) :	14.63
MACD	MACD :	0.4	Signal :	0.4
%K %D	K(14,3) :	73.3	D(3) :	81.1
RSI	RSI(14): 64.2
52-week	High :	16.47	Low :	12.8

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ TAK ] has closed below upper band by 37.7%. Bollinger Bands are 11.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	16.26 - 16.4	16.4 - 16.48
Low:	15.63 - 15.78	15.78 - 15.88
Close:	15.96 - 16.19	16.19 - 16.34

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Tue, 13 Jan 2026
Takeda (TAK) Gains Analyst Confidence with Promising Drug Develo - GuruFocus

Mon, 12 Jan 2026
Takeda Pharmaceutical Company L (TAK): Investor Outlook with 8.38% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews

Mon, 05 Jan 2026
Experimental polycythemia vera drug could cut constant blood draws - Stock Titan

Thu, 11 Dec 2025
Takeda: Lack Of Realistic Upside In Japanese Pharma (NYSE:TAK) - Seeking Alpha

Thu, 30 Oct 2025
Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges - Sahm

Wed, 29 Oct 2025
Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS) - TradingView — Track All Markets

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	3,160 (M)
Shares Float	1,580 (M)
Held by Insiders	0 (%)
Held by Institutions	2.7 (%)
Shares Short	10,390 (K)
Shares Short P.Month	11,380 (K)

EPS	0.05
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	28.45
Profit Margin	0.7 %
Operating Margin	15.2 %
Return on Assets (ttm)	2 %
Return on Equity (ttm)	0.4 %
Qtrly Rev. Growth	-5.5 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	748,480 (M)

PE Ratio	269.16
PEG Ratio	0
Price to Book value	0.56
Price to Sales	1.15462e+010
Price to Cash Flow	4.25283e+010

Dividend	0.34
Forward Dividend	0
Dividend Yield	2.1%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.